Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
GB Sciences, Inc. is a biotechnology company focused on the research and development of cannabinoid-based medicines. The company operates primarily in the pharmaceutical research and life sciences industry, with an emphasis on developing therapeutic products derived from cannabis and other plant-based compounds. Its business model centers on early-stage drug discovery, preclinical research, and intellectual property development rather than commercial-scale product sales.
The company’s core focus has been on cannabinoid formulations targeting neurological and metabolic disorders, including conditions such as Parkinson’s disease and other central nervous system indications. GB Sciences positions itself as a science-driven organization seeking to differentiate through patented formulations, proprietary delivery methods, and a research-oriented approach rather than recreational cannabis production. The company was founded in 2014 and evolved from a broader life sciences focus into a cannabinoid-centric research platform as regulatory frameworks for medical cannabis expanded in the United States.
Business Operations
GB Sciences generates minimal operating revenue and is primarily engaged in research, development, and administrative activities. Its principal business activities include laboratory research, formulation development, preclinical testing, and regulatory planning related to cannabinoid-based drug candidates. The company does not operate large-scale manufacturing or commercial distribution, and its operations are largely funded through equity financing.
The company’s operations have been primarily domestic within the United States, with laboratory and administrative activities historically centered in Nevada. GB Sciences controls intellectual property related to cannabinoid formulations and delivery technologies, but it does not currently report material revenue-generating subsidiaries or active joint ventures. Public disclosures indicate limited operational scale, and financial filings consistently describe the company as being in a development-stage phase. Data inconclusive based on available public sources regarding any active revenue-producing partnerships.
Strategic Position & Investments
Strategically, GB Sciences has focused on advancing its cannabinoid drug candidates through preclinical development while seeking strategic alternatives to fund further research, including potential licensing arrangements, collaborations, or capital raises. The company has publicly stated its intent to protect and monetize intellectual property related to therapeutic cannabinoid formulations.
GB Sciences has not disclosed material acquisitions or significant equity investments in external companies. Its investment activity appears limited to internal research spending and patent-related costs. While the company has referenced emerging therapeutic applications of cannabinoids and alternative delivery systems, publicly available filings do not confirm advancement into late-stage clinical trials or commercialization. As such, its strategic position remains that of an early-stage biotechnology developer with high dependency on future financing.
Geographic Footprint
The company’s operational footprint is concentrated in North America, specifically the United States. GB Sciences has historically identified Nevada as its principal place of business, reflecting its administrative headquarters and research activities. There is no verified evidence of material international operations, overseas laboratories, or foreign subsidiaries.
Although the company has referenced global pharmaceutical markets in its strategic disclosures, public filings do not indicate active commercial operations, manufacturing, or research facilities outside the United States. Any international influence appears limited to the potential future applicability of its intellectual property rather than current operational presence.
Leadership & Governance
GB Sciences was founded by Roger R. Kruse – Founder and Executive Chairman, who has played a central role in shaping the company’s research-focused strategy and cannabinoid development vision. Leadership has emphasized scientific rigor, intellectual property protection, and long-term pharmaceutical development over short-term commercialization.
Key executives disclosed in public filings include:
- Roger R. Kruse – Executive Chairman
- Mark L. Bradford – Chief Financial Officer
- John Poss – Director
The company’s governance structure reflects its small size and development-stage status, with a limited executive team overseeing strategy, finance, and compliance. Leadership philosophy, as described in filings, centers on disciplined capital management and advancing cannabinoid science within regulated pharmaceutical frameworks.